Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
BSX

BSX - Boston Scientific Corp Stock Price, Fair Value and News

74.66USD+0.11 (+0.15%)Market Closed

Market Summary

BSX
USD74.66+0.11
Market Closed
0.15%

BSX Alerts

  • 4 major insider sales recently.
  • Big jump in Earnings (Y/Y)

BSX Stock Price

View Fullscreen

BSX RSI Chart

BSX Valuation

Market Cap

109.8B

Price/Earnings (Trailing)

61.98

Price/Sales (Trailing)

7.46

EV/EBITDA

32.15

Price/Free Cashflow

64.64

BSX Price/Sales (Trailing)

BSX Profitability

EBT Margin

14.61%

Return on Equity

8.78%

Return on Assets

4.83%

Free Cashflow Yield

1.55%

BSX Fundamentals

BSX Revenue

Revenue (TTM)

14.7B

Rev. Growth (Yr)

13.78%

Rev. Growth (Qtr)

3.52%

BSX Earnings

Earnings (TTM)

1.8B

Earnings Growth (Yr)

57.01%

Earnings Growth (Qtr)

-2.18%

Breaking Down BSX Revenue

Last 7 days

1.3%

Last 30 days

9.9%

Last 90 days

13.4%

Trailing 12 Months

39.7%

How does BSX drawdown profile look like?

BSX Financial Health

Current Ratio

1.66

Debt/Equity

0.47

Debt/Cashflow

0.26

BSX Investor Care

Shares Dilution (1Y)

2.26%

Diluted EPS (TTM)

1.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202414.7B000
202313.0B13.4B13.8B14.2B
202212.2B12.3B12.6B12.7B
202110.1B11.2B11.5B11.9B
202010.8B10.2B10.1B9.9B
20199.9B10.1B10.4B10.7B
20189.3B9.5B9.7B9.8B
20178.6B8.7B8.8B9.0B
20167.7B8.0B8.2B8.4B
20157.4B7.3B7.4B7.5B
20147.2B7.2B7.3B7.4B
20137.1B7.1B7.1B7.1B
20127.6B7.4B7.3B7.2B
20117.8B7.8B7.8B7.6B
20108.1B8.0B7.9B7.8B
20098.0B8.1B8.1B8.2B
200808.3B8.2B8.1B
20070008.4B

Tracking the Latest Insider Buys and Sells of Boston Scientific Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 07, 2024
dockendorff charles j
sold
-286,874
72.7
-3,946
-
May 02, 2024
butcher arthur c
acquired
-
-
2,102
evp& grp pres, medsurg & apac
May 02, 2024
sorenson john bradley
acquired
-
-
4,203
evp, global operations
May 02, 2024
butcher arthur c
sold (taxes)
-73,254
72.03
-1,017
evp& grp pres, medsurg & apac
May 02, 2024
sorenson john bradley
sold (taxes)
-138,082
72.03
-1,917
evp, global operations
May 01, 2024
carruthers wendy
sold
-499,075
71.47
-6,983
evp, human resources
May 01, 2024
carruthers wendy
acquired
82,305
19.3069
4,263
evp, human resources
May 01, 2024
sorenson john bradley
acquired
303,552
17.26
17,587
evp, global operations
May 01, 2024
sorenson john bradley
sold
-1,257,490
71.501
-17,587
evp, global operations
Apr 26, 2024
ludwig edward j
sold
-719,562
73.2901
-9,818
-

1–10 of 50

Which funds bought or sold BSX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
Beacon Capital Management, LLC
added
11,420
39,186
39,450
0.01%
May 16, 2024
COMERICA BANK
reduced
-1.7
2,674,760
18,929,800
0.08%
May 16, 2024
TANDEM CAPITAL MANAGEMENT CORP /ADV
reduced
-0.21
615,962
3,996,460
2.27%
May 16, 2024
B. Riley Wealth Advisors, Inc.
added
51.97
240,142
859,056
0.02%
May 16, 2024
Ancora Advisors LLC
reduced
-3.54
27,791
222,338
-%
May 16, 2024
Pineridge Advisors LLC
reduced
-8.2
309
3,835
-%
May 16, 2024
Fairbanks Capital Management, Inc.
reduced
-1.53
265,690
1,860,670
1.28%
May 16, 2024
FSA Wealth Management LLC
unchanged
-
1,000
5,000
-%
May 16, 2024
Meiji Yasuda Life Insurance Co
added
49.57
2,046,040
4,696,220
0.10%
May 16, 2024
WealthPlan Investment Management, LLC
new
-
204,306
204,306
0.03%

1–10 of 46

Are Funds Buying or Selling BSX?

Are funds buying BSX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BSX
No. of Funds

Unveiling Boston Scientific Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.56%
125,449,595
SC 13G/A
Feb 09, 2024
massachusetts financial services co /ma/
3.9%
57,175,974
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 25, 2024
blackrock inc.
8.7%
127,036,665
SC 13G/A
Feb 14, 2023
blackrock inc.
9.6%
137,802,646
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.29%
118,773,794
SC 13G/A
Feb 08, 2023
massachusetts financial services co /ma/
5.8%
82,467,469
SC 13G/A
Feb 06, 2023
wellington management group llp
4.03%
57,736,340
SC 13G/A
Jan 24, 2023
blackrock inc.
9.8%
140,116,265
SC 13G/A

Recent SEC filings of Boston Scientific Corp

View All Filings
Date Filed Form Type Document
May 14, 2024
4
Insider Trading
May 13, 2024
4
Insider Trading
May 13, 2024
4
Insider Trading
May 13, 2024
4
Insider Trading
May 13, 2024
4
Insider Trading
May 13, 2024
4
Insider Trading
May 13, 2024
4
Insider Trading
May 13, 2024
4
Insider Trading
May 13, 2024
4
Insider Trading
May 13, 2024
4
Insider Trading

Peers (Alternatives to Boston Scientific Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.0B
40.3B
-1.75% -4.07%
32.18
4.49
-2.84% -3.08%
68.3B
19.7B
1.78% -6.05%
51.24
3.46
4.82% -17.56%
20.4B
3.9B
-9.57% -7.50%
44.2
5.22
5.72% 46.72%
18.0B
14.9B
-10.73% -18.01%
6.79
1.21
2.98% 207.68%
MID-CAP
9.8B
3.5B
6.68% 24.08%
31.27
2.76
6.16% 35.06%
9.6B
12.5B
6.31% -2.51%
24.63
0.77
-0.61% -18.83%
8.4B
2.6B
1.13% -22.65%
-26.02
3.22
-6.25% -68.62%
5.9B
3.9B
-6.79% -30.12%
-62.84
1.49
0.23% 91.03%
3.4B
387.1M
0.52% 31.17%
-216.3
8.9
30.82% 65.57%
2.3B
6.6B
0.19% -5.50%
11.93
0.35
2.78% -0.87%
SMALL-CAP
1.3B
3.2B
5.94% -10.00%
-1.91
0.41
7.94% -1661.78%
376.6M
169.3M
-1.13% -2.23%
-4.9
2.23
7.49% -244.90%
241.9M
324.0M
-4.58% -37.15%
-1.26
0.75
-3.19% -337.41%
56.1M
50.5M
22.73% -73.49%
-2.46
1.11
14.25% -10.06%
1.1M
3.7M
-71.13% 32.26%
-0.09
0.29
5.77% 8.23%

Boston Scientific Corp News

Latest updates
Defense World25 hours ago
Yahoo Finance14 May 202404:14 pm
PR Newswire24 Apr 202407:00 am

Boston Scientific Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue3.5%3,8563,7253,5273,5993,3893,2423,1703,2443,0263,1272,9323,0772,7522,7092,6592,0032,5432,9042,7072,6312,493
Gross Profit2.7%2,6482,5792,4262,5422,3492,2322,1912,2332,0712,1552,0322,1321,8581,7091,7901,2121,7372,0541,9301,8731,763
Operating Expenses-1.1%1,9731,9951,7332,0281,7971,8301,8331,8101,6051,9751,6451,8701,4881,6591,9951,2831,5911,8441,5471,4891,222
  S&GA Expenses-1.1%1,3641,3791,2421,3541,2151,1631,1321,1651,0601,1531,0661,1211,0191,0279847989781,0921,012968869
EBITDA Margin2.1%0.25*0.24*0.24*0.22*0.22*0.22*0.20*0.22*0.21*0.21*0.24*0.18*---------
Interest Expenses7.0%69.0065.0066.0070.0065.0064.0063.0064.0027987.0086.0086.0082.0096.0086.0091.0088.0018095.0089.00109
Income Taxes11400.0%1151.0010515613125657.0085.0045.0026.0064.00-37.00-16.0096.00-72.00-33.0012.00-4,002-35.00-9.0033.00
Earnings Before Taxes20.4%608505610426444396245345156119483149325307-227-18122.00-6.0091.00145457
EBT Margin4.8%0.15*0.14*0.14*0.11*0.11*0.09*0.07*0.09*0.07*0.09*0.11*0.05*---------
Net Income-2.2%49350450427031414018826011095.00419186341210-155-14711.003,996126154424
Net Income Margin7.7%0.12*0.11*0.09*0.07*0.07*0.06*0.05*0.07*0.07*0.09*0.10*0.05*---------
Free Cashflow-102.2%-15.0069050851579.00595320202-179212358537---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets4.4%36,66935,13634,04333,60132,89232,46931,94732,18932,33732,22931,87731,16830,90030,77730,84530,82330,11330,56526,75624,30923,802
  Current Assets25.7%8,1856,5146,5045,8865,7045,7605,1445,0835,0656,3176,2296,7586,1016,6946,1605,8034,8234,6994,8476,3346,234
    Cash Equivalents188.6%2,4968659524265709283382763251,9251,9472,6752,0161,9952,0221,724370607277123139
  Inventory3.1%2,5612,4842,4042,2502,0501,8671,7881,7521,7361,6101,6031,4301,4071,3511,4721,5161,6281,5791,5661,3001,228
  Net PPE1.3%2,8972,8592,6352,5342,4782,4462,2732,2462,2652,2522,1092,0822,0532,0842,0642,0792,0982,0791,9421,8201,782
  Goodwill-0.2%14,36114,38713,60813,65913,26912,92012,85212,88312,94911,98811,82010,87410,8689,95110,13710,10110,09810,17610,0158,4518,179
  Current Liabilities-0.3%4,9164,9334,5794,5624,0833,8033,5493,8834,2754,2744,0224,0733,3933,6813,3023,1083,9764,8664,2544,8504,479
  Long Term Debt11.2%9,5348,5718,3868,4948,4958,9158,5648,8029,0678,8048,8248,8479,0829,1309,3259,2789,3318,5929,5907,5917,590
Shareholder's Equity4.6%20,16819,28218,88617.0017817,57317,64017,25116,73516,62216,46223717.0019,73215,56417.0016.0027017,51017,42287.00
  Retained Earnings60.4%1,314819315-189-450-750-876-1,050-1,296-1,392-1,473-1,878-2,050-2,378-2,574-2,405-2,252-2,253-6,249-6,375-6,528
  Additional Paid-In Capital0.3%20,71320,64720,57320,44120,35620,28920,21920,10320,04319,98619,93019,81719,75019,73219,68719,59017,58917,56117,51017,42217,374
Shares Outstanding1.1%1,4681,4531,4491,4411,4361,4311,4321,4291,4281,4221,4211,420---------
Minority Interest-2.4%242248243259259----------------
Float----79,000-------53,200---50,000---53,100-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-82.9%164957698658190807470307-58.00478465643284673643269-77.00692502292350
  Share Based Compensation6.8%63.0059.0059.0060.0055.0055.0058.0055.0052.0049.0051.0047.0047.0042.0040.0046.0042.0041.0042.0038.0036.00
Cashflow From Investing72.9%-285-1,053-197-840-484-183-225-29.00-1,574-461-1,207-71.00-147-129-59.00-76.00-49.00-3,962-620-410
Cashflow From Financing10360.0%1,56915.0016.0043.00-69.001.00-199-344-6.00-8.006.002.00-95.00-819-2491,105256-7241,3142562,127
  Dividend Payments----14.0014.0013.0014.0014.0014.0013.0014.0014.0014.00--------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BSX Income Statement

2024-03-31
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Net sales$ 3,856$ 3,389
Cost of products sold1,2091,040
Gross profit2,6482,349
Operating expenses:  
Selling, general and administrative expenses1,3641,215
Research and development expenses366337
Royalty expense1011
Amortization expense214203
Contingent consideration net expense (benefit)1712
Restructuring net charges (credits)320
Operating expenses1,9731,797
Operating income (loss)675552
Other income (expense):  
Interest expense(69)(65)
Other, net2(43)
Income (loss) before income taxes608444
Income tax expense (benefit)115131
Net income (loss)493314
Preferred stock dividends0(14)
Net income (loss) attributable to noncontrolling interests(1)0
Net income (loss) attributable to Boston Scientific common stockholders$ 495$ 300
Net income (loss) per common share — basic$ 0.34$ 0.21
Net income (loss) per common share — diluted$ 0.33$ 0.21
Weighted-average shares outstanding  
Basic1,468.41,435.8
Diluted1,481.71,446.0

BSX Balance Sheet

2024-03-31
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 2,329$ 865
Trade accounts receivable, net2,3042,228
Inventories2,5612,484
Prepaid income taxes319315
Other current assets671621
Total current assets8,1856,514
Property, plant and equipment, net2,8972,859
Goodwill14,36114,387
Other intangible assets, net5,8396,003
Deferred tax assets3,7923,841
Other long-term assets1,5961,531
TOTAL ASSETS36,66935,136
Current liabilities:  
Current debt obligations1,085531
Accounts payable921942
Accrued expenses2,0832,646
Other current liabilities827814
Total current liabilities4,9164,933
Long-term debt9,5348,571
Deferred income taxes132134
Other long-term liabilities1,9191,967
Commitments and contingencies
Stockholders’ equity  
Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of March 31, 2024 and December 31, 202300
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,733,293,885 shares as of March 31, 2024 and 1,729,000,224 shares as of December 31, 20231717
Treasury stock, at cost - 263,289,848 shares as of March 31, 2024 and December 31, 2023(2,251)(2,251)
Additional paid-in capital20,71320,647
Retained earnings1,314819
Accumulated other comprehensive income (loss), net of tax13249
Total stockholders’ equity19,92619,282
Noncontrolling interests242248
Total equity20,16819,530
TOTAL LIABILITIES AND EQUITY$ 36,669$ 35,136
Preferred Stock, Shares Issued00
BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
 CEO
 WEBSITEbostonscientific.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES45000

Boston Scientific Corp Frequently Asked Questions


What is the ticker symbol for Boston Scientific Corp? What does BSX stand for in stocks?

BSX is the stock ticker symbol of Boston Scientific Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Boston Scientific Corp (BSX)?

As of Fri May 17 2024, market cap of Boston Scientific Corp is 109.76 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BSX stock?

You can check BSX's fair value in chart for subscribers.

What is the fair value of BSX stock?

You can check BSX's fair value in chart for subscribers. The fair value of Boston Scientific Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Boston Scientific Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BSX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Boston Scientific Corp a good stock to buy?

The fair value guage provides a quick view whether BSX is over valued or under valued. Whether Boston Scientific Corp is cheap or expensive depends on the assumptions which impact Boston Scientific Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BSX.

What is Boston Scientific Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BSX's PE ratio (Price to Earnings) is 61.98 and Price to Sales (PS) ratio is 7.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BSX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Boston Scientific Corp's stock?

In the past 10 years, Boston Scientific Corp has provided 0.194 (multiply by 100 for percentage) rate of return.